Atazanavir atazanavir is a structural analog of the transition state during which the bond between a phenylalanine and proline is broken. Humans do not have any enzymes that break bonds between phenylalanine and proline, so this drug will not target human enzymes. Atazanavir is available as a 150 mg capsule, 200 mg capsule, 300 mg capsule, and 50 mg oral powder packet. The 300 mg capsule should reduce pill burden, as one 300 mg capsule may replace two 150 mg capsules. Atazanavir Atazanavir, sold under the trade name Reyataz among others, is an antiretroviral medication used to treat and prevent HIV/AIDS.
Microbial drug delivery has been used to treat forms of inflammatory bowel disease (IBD). The most prominently studied vehicles of microbial drug administration are the bacterial species, "Lactococcus lactis" and "Bacteroides ovatus." The usage of recombinant microbes (i.e. microorganisms designed to contain DNA from two or more different species) has applications in treating chronic diseases. In 2006, Braat "et al". implemented microbial drug delivery with "L. lactis" in clinical trials, successfully treating Crohn’s disease (CD), a form of IBD that causes inflammation and ulceration in the intestines. In this study, a recombinant strain of "L. lactis" containing complimentary DNA (cDNA) for the human